If the FDA approves the test, it could pave the way for Medicare coverage, potentially impacting cancer screening practices and access to early detection for patients across the country.
Watch for the FDA's decision on the Galleri test, as approval could lead to significant shifts in cancer screening protocols. Stakeholders should monitor Medicare's response and the implications for early detection strategies in oncology.